



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke and Scoville

Application No.: 10/008,574

Filed: October 26, 2001

Group Art Unit: 1645

Title: Novel Human 7TM Proteins and Polynucleotides
Encoding the Same

Examiner: To Be Assigned

Attorney Docket No.: LEX-0264-USA

Assistant Commissioner for Patents
Box DD
Arlington, VA 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

under 37 CFR 1.97(c) together with either a:

Certification under 37 CFR 1.97(e), or

a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with a:

Certification under 37 CFR 1.97(e), and

a petition under 37 CFR 1.97(d)(2)(ii), and

a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

I declare that I am a patent attorney, patent agent, or other individual, or a member of the bar, or a law firm, or a corporation, or other entity, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

March 19, 2003
Date

Lance K. Ishimoto *3/19/03* *Reg. No. 41,866*
Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A PTO

1
MAR 1974
**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Shee

1 of

1

Complete if Known

Application Number	10/008,574
Filing Date	Oct 26, 2001
First Named Inventor	Walke
Group Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	LEX-0264-USA

U. S. PATENT DOCUMENTS

CITED PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY
		Number	Kind Code* (if known)		

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office	Number ⁴	Kind Code ⁵ (if known)				
	DX		WO 02 22665 A		Takeda Chemical Industries	03-21-2002		
	DY		WO 02 26825 A		Incyte Genomics	04-04-2002		
	DZ		WO 02 29050 A		Bayer Aktiengesellschaft	04-11-2002		
	EA		WO 02 29051 A		Bayer Aktiengesellschaft	04-11-2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EB	DATABASE EMBL 19 May 2000, CORBY N.: "Human DNA sequence from clone RP11-550C4 on chromosome 6", Database accession no. AL356421, XP002229817, Positions 56940-58380	
	EC	DATABASE EMBL 22 March 2000, SIMS S.: "Human DNA sequence from clone RP11-337K13 *Sequencing cancelled*", Database accession no. AL161776, XP002229818, Positions 119530-120990	
	ED	ICHTCHENKO K ET AL: "A NOVEL UBIQUITOUSLY EXPRESSED ALPHA-LATROTOXIN RECEPTOR IS A MEMBER OF THE CIRL FAMILY OF G-PROTEIN-COUPLED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 9, 26 February 1999, pages 5491-5498, XP000828192, ISSN: 0021-9258	
	EE	LELIANOVA V G ET AL: "ALPHA-LATROTOXIN RECEPTOR, LATROPHILIN, IS A NOVEL MEMBER OF THE SECRETIN FAMILY OF G PROTEIN-COUPLED RECEPTORS: JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS. BALTIMORE, MD, US, vol. 272, no. 34, 22 August 1997, pages 21504-21508, XP002066460, issn: 0021-9258	
	EF	OSTERHOFF C ET AL: "CLONING OF A HUMAN EPIDIDYMIS-SPECIFIC mRNA, HE6, ENCODING A NOVEL MEMBER OF THE SEVEN TRANSMEMBRANE-DOMAIN RECEPTOR SUPERFAIMLY" DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 16, no. 4, 1997, pages 379-389, XP002925525, ISSN: 1044-5498	
	EG	STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 11, 1 November 1997, pages 430-437, XP004099345, ISSN 0165-6147.	
	EH	SUGITA S ET AL: "ALPHA-LATROTOXIN RECEPTOR CIRL/LATROPHILIN 1 (CL1) DEFINES AN UNUSUAL FAMILY OF UBIQUITOUS G-PROTEIN-LINKED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., US, vol. 273, no. 49, 1998, pages 32715-32724, XP000946649, issn: 0021-9258	
	EI	International Search Report	

THE BOSTONIAN

¹⁰ See, for example, the discussion of the role of the state in the development of the economy in the 1950s and 1960s in the Soviet Union in the work of G. A. Shmelev, *State and Economy in the USSR* (Moscow, 1989).

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the complexity of the case. An estimate of the cost of this form is \$1.00.

Please type a plus sign (+) inside this box →

PTO-SB-21 (08-00)

Approval for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

MAR 24

1645

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/008,574
		Filing Date	Oct 26, 2001
		First Named Inventor	Walke, D. Wade
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	5 pgs + 12 references	Attorney Docket Number	LEX-0264-USA


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Return Postcard - Supplemental Form PTO1449 and Copies of (12) References Cited - International Search Report as Ref El
<input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866	
Signature		24231 PATENT TRADEMARK OFFICE
Date	March 19, 2003	

CERTIFICATE OF MAILING

Typed or printed name	Michèle Klein		
Signature		Date	March 19, 2003